Methotrexate injection for new rheumatoid arthritis patients
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not taken methotrexate before (any form, pill or injection).
- You are 18 years or older.
- Your rheumatoid arthritis is considered moderate to severe (active joint swelling and pain).
- You have not used any biologic drugs (like Humira) or JAK inhibitors (like Xeljanz) for RA.
- You are able to have regular check-ups and blood tests during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well methotrexate injections work in people with rheumatoid arthritis. It is designed for patients who are starting or changing to this type of methotrexate treatment.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests whether adding silymarin (a natural supplement from milk thistle) to standard methotrexate treatment can improve symptoms of rheumatoid arthritis. It may help reduce joint pain and swelling for people who are not yet in remission.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This study compares two oral medications, tofacitinib and upadacitinib, when added to methotrexate for people with rheumatoid arthritis. The goal is to see which one works better and is safer for controlling symptoms.
This trial tests whether adding empagliflozin to methotrexate helps reduce rheumatoid arthritis activity compared to methotrexate alone. It may protect joints from further damage.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.